Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.

Edwards Lifesciences' Pascal device and its emerging portfolio of transcatheter mitral technologies are likely to put pressure on Abbott's MitraClip franchise over the longer term. Abbott remains ...

The MitraClip, one of the company’s flagship structural heart devices, has been growing steadily as more doctors adopt non-invasive heart valve repair procedures. Abbott is also betting big on ...

Moreover, Abbott is an established leader in TEER space with its MitraClip system. We expect the market sentiment toward ABT stock to remain positive surrounding the latest development.

Oz helped invent and holds a patent on MitraClip, which is now owned by Abbott. MitraClip received a CE mark in 2008, Oz said, but it took five more years for the FDA to approve the device and ...

Abbott Laboratories (NYSE ... and strong momentum in structural heart devices, including MitraClip and TriClip. Overall, ABT ranks 8th on our list of best diabetes stocks to buy according to ...

Abbott Laboratories (NYSE ... and strong momentum in structural heart devices, including MitraClip and TriClip.

Oz helped invent and holds a patent on MitraClip, which is now owned by Abbott. MitraClip received a CE mark in 2008, Oz said, but it took five more years for the FDA to approve the device and another ...

Abbott makes the MitraClip repair device that treats mitral valve regurgitation and the TriClip device for tricuspid regurgitation. Edwards has the Pascal system for mitral and tricuspid valve repair.